Engert et al. Reduced treatment intensity in patients with early-stage Hodgkin’s lymphoma. N Engl J Med. 2010 Aug 12;363(7):640-52. doi: 10.1056/NEJMoa1000067. http://www.ncbi.nlm.nih.gov/pubmed/20818855
Engert et al. Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin’s lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial. Lancet. 2012 May 12;379(9828):1791-9. doi: 10.1016/S0140-6736(11)61940-5. Epub 2012 Apr 4. http://www.ncbi.nlm.nih.gov/pubmed/22480758
Josting et al. Dose intensity of chemotherapy in patients with relapsed Hodgkin’s lymphoma. J Clin Oncol. 2010 Dec 1;28(34):5074-80. doi: 10.1200/JCO.2010.30.5771. Epub 2010 Oct 25. http://www.ncbi.nlm.nih.gov/pubmed/20975066
Younes et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin’s lymphoma. J Clin Oncol. 2012 Jun 20;30(18):2183-9. doi: 10.1200/JCO.2011.38.0410. Epub 2012 Mar 26.
http://www.ncbi.nlm.nih.gov/pubmed/22454421